Skip to main content
. 2018 Aug 9;4(11):1569–1575. doi: 10.1001/jamaoncol.2018.3039

Figure 2. Kaplan-Meier Estimates of Overall and Progression-Free Survival.

Figure 2.

A, For the anlotinib group, the median overall survival (OS) was 9.6 months (95% CI, 8.2-10.6); for the placebo group, the median OS was 6.3 months (95% CI, 5.0-8.1). The hazard ratio (HR) was 0.68 (95% CI, 0.54-0.87; P = .002). B, For the anlotinib group, the median progression-free survival (PFS) was 5.4 months (95% CI, 4.4-5.6). For the placebo group, the median PFS was 1.4 months (95% CI, 1.1-1.5). The HR was 0.25 (95% CI, 0.19-0.31; P < .001).